Global non-small cell lung cancer drugs market size is forecast to grow by USD 14.28 billion during 2019-2023 at a CAGR of 13%, with biologics segment having the largest market share. Non-small cell lung cancer drugs market analysis indicates growth will be driven by the strong drug pipeline and drug approvals. Non-small cell lung cancer drugs industry growth will also be impacted by the use of predictive biomarkers for the development of cost-effective therapies.
